两融数据显示，该股最新（8月18日）两融余额为9.20亿元，其中，融资余额为9.20亿元，近10日增加 5.65亿元，环比增长159.54%。 赛诺医疗股价创出历史新高，截至9:36，该股上涨8.41%，股价报44.97元，成交量1212.77万股，成交金 额5.32亿元，换手率2.91%，该股最新A股总市值达187.10亿元，该股A股流通市值187.10亿元。 证券时报•数据宝统计显示，赛诺医疗所属的医药生物行业，目前整体涨幅为1.20%，行业内，目前股价 上涨的有410只，涨停的有福瑞股份、济民健康等3只。股价下跌的有73只，跌幅居前的有南模生物、皓 宸医疗、广誉远等，跌幅分别为4.85%、4.01%、3.58%。 7月25日公司发布上半年业绩预告，预计实现净利润1384.00万元，同比同比增长296.54%。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 公司发布的一季报数据显示，一季度公司共实现营业收入1.01亿元，同比增长10.75%，实现净利润 296.93万元，同比增长277.50%，基本每股收益为0.0100元，加权平均净资产收益率0.34%。 ...

赛诺医疗(688108.SH)发布股票交易严重异常波动公告，公司股票交易于2025年8月14日、2025年8月15 日、2025年8月18日连续3个交易日内日收盘价格涨幅偏离值累计达到30%;公司股票交易于2025年8月7 日至2025年8月18日连续10个交易日内3次出现连续3个交易日收盘价格涨幅偏离值累计达到30%，根据 《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于 股票交易严重异常波动情形。 经自查，公司目前日常生产经营情况正常，市场环境、行业政策等均未发生重大调整。敬请广大投资者 注意投资风险。 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-035 赛诺医疗科学技术股份有限公司 关于股票交易严重异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）股票交 易于 2025 年 8 月 14 日、2025 年 8 月 15 日、2025 年 8 月 18 日连续 3 个交易日内日收 盘价格涨幅偏离值累计达到 30%；公司股票交易于 2025 年 8 月 7 日至 2025 年 8 月 18 日连续 10 个交易日内 3 次出现连续 3 个交易日收盘价格涨幅偏离值累计达到 30%，根 据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》 的有关规定，属于股票交易严重异常波动情形。 经公司自查，公司于 2025 年 7 月 22 日发布了《赛诺医疗关于公司新型药物洗 脱支架系统获得美国 FDA 附条件批准的自愿性披露公告》（公告编号：2025-029），于 2025 年 7 月 25 日发布了《 ...

格隆汇8月19日｜赛诺医疗发布关于股票交易严重异常波动的公告，公告称，截至公告日，公司控股股 东、实际控制人及其一致行动人不存在影响公司股票交易异常波动的重大事项，不存在其他应披露而未 披露的重大信息。截至2025年8月18日，公司股票收盘价为41.48元/股，近期公司股价累计涨幅较大， 超过大部分同行业公司股价涨幅及上证指数涨幅，可能存在短期上涨过快出现的下跌风险。 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][34]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 3.08% from August 11 to August 15, 2025, ranking 10th among 31 industries and outperforming the CSI 300 index by 0.71 percentage points. Year-to-date, the sector has risen by 25.02%, ranking 4th among the industries and outperforming the CSI 300 index by 18.22 percentage points [4][14]. - The current PE valuation for the pharmaceutical and biotechnology sector is 31.31 times, which is at the historical median level, with a valuation premium of 145% compared to the CSI 300 index [4][20]. - Key sub-sectors that performed well include medical services, chemical pharmaceuticals, and medical devices, with respective increases of 6.60%, 3.80%, and 2.22% [4][13]. Market Performance - The pharmaceutical and biotechnology sector's performance for the week of August 11-15, 2025, showed a 3.08% increase, ranking 10th among 31 industries, and outperforming the CSI 300 index by 0.71 percentage points. Year-to-date, the sector has increased by 25.02%, ranking 4th among industries and outperforming the CSI 300 index by 18.22 percentage points [4][14]. - The top three performing sub-sectors were medical services, chemical pharmaceuticals, and medical devices, with increases of 6.60%, 3.80%, and 2.22% respectively [4][13]. Industry News - On August 12, 2025, the National Medical Insurance Administration announced the preliminary review list of drugs for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, with 534 drugs passing the basic medical insurance review and 121 passing the commercial insurance review [5][28]. - On August 15, 2025, the National Medical Insurance Administration issued a temporary management method for disease-based payment, aimed at reforming the payment method primarily based on disease categories [5][29]. - On August 15, 2025, Novo Nordisk announced that the supplemental new drug application for semaglutide (Wegovy) was approved by the FDA for treating metabolic dysfunction-associated fatty liver disease (MASH) in patients with mid-to-late stage liver fibrosis [5][30]. Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector continues to strengthen after a slight adjustment, outperforming the broader market index. It recommends focusing on investment opportunities in innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][31]. - Recommended stocks include Betta Pharmaceuticals, Teva Pharmaceutical, Kaili Medical, Anjies, and Huaxia Eye Hospital, while stocks to watch include Kelun Pharmaceutical, Qianhong Pharmaceutical, Haier Biomedical, Kangtai Biological, and Baipusais [6][31].

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...

Group 1 - The medical device sector has shown strong performance, with the medical device ETF (562600) rising by 5% recently, and key holdings like Furuida and Sino Medical hitting a 20% limit up [1] - The National Healthcare Security Administration (NHSA) has outlined the achievements of the healthcare reform during the 14th Five-Year Plan and the focus areas for the upcoming 15th Five-Year Plan, providing clear direction for the development of the medical device industry [1] - The 11th round of centralized procurement emphasizes four principles: maintaining clinical stability, ensuring quality, preventing collusion, and avoiding internal competition, aiming to promote high-quality products rather than just low prices [1] Group 2 - Recent trends indicate ongoing international business collaborations in innovative pharmaceuticals, with a focus on the medical device sector gaining traction due to policies related to brain-computer interfaces [2] - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device industry, tracking the CSI All Share Medical Device Index, which includes 100 representative companies [2] - The medical device industry constitutes a significant 89.34% of the index, highlighting its concentrated nature and ability to capture the development dividends in the sector [2]

Core Insights - The stock of Sainuo Medical has increased by 19.99%, achieving four trading halts within eight trading days, with a latest price of 41.48 yuan and a total market capitalization of 17.258 billion yuan [1] Group 1: Company Developments - Sainuo Medical's subsidiary, Sainuo Shenchang, has received breakthrough medical device designation from the FDA for its COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter, marking it as the world's first product for treating intracranial atherosclerotic stenosis and the first domestic neuro-interventional device to achieve this recognition, enhancing its technological leadership in the neuro-interventional field [1] Group 2: Industry Context - According to a report from CITIC Securities, the high-level policy direction emphasizes "anti-involution" and "optimizing centralized procurement not solely based on low prices," which supports the development of innovative medical device industries and enhances expectations for industry valuation recovery [1] - Sainuo Medical is primarily involved in sectors such as medical devices, neuro-intervention, cardiovascular intervention, brain-computer interfaces, and centralized procurement [1]

Core Viewpoint - Sino Medical achieved a significant stock price increase of 19.99% on August 18, reaching a price of 41.48 CNY per share, with a trading volume of 2.032 billion CNY and a turnover rate of 12.37%, resulting in a total market capitalization of 17.258 billion CNY [1] Company Overview - Sino Medical Technology Co., Ltd. is located in the Tianjin Economic-Technological Development Area and specializes in the research, production, and sales of high-end interventional medical devices [1] - The company’s main products include coronary drug-eluting stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents, with over 1.4 million units used globally, serving hundreds of thousands of patients [1] - Sino Medical holds 8 key technologies, has launched 19 products, and possesses over 200 global patents, while undertaking 7 national and provincial scientific research projects [1] - Clinical research results of its products have been published in 31 articles in core domestic and international journals [1] Financial Performance - For the period from January to March 2025, Sino Medical reported a revenue of 101 million CNY, representing a year-on-year growth of 10.75% [1] - The net profit attributable to shareholders was 2.9693 million CNY, showing a substantial year-on-year increase of 277.50% [1] - As of March 31, the number of shareholders was 11,000, with an average of 37,400 circulating shares per person [1]

从个股来看，8月15日有255只科创板个股获融资净买入，净买入金额在5000万元以上的有16股。其中， 寒武纪获融资净买入额居首，净买入1.83亿元；融资净买入金额居前的还有华虹公司、赛诺医疗、东芯 股份、腾景科技、中芯国际、神州细胞等股，净买入额分别为1.27亿元、1.21亿元、1.15亿元、1.06亿 元、1.02亿元、0.99亿元。 （文章来源：证券时报网） Wind统计显示，8月15日，科创板两融余额合计1902.7亿元，较上一交易日增加9.88亿元。其中，融资 余额合计1896.43亿元，较上一交易日增加10.18亿元；融券余额合计6.27亿元，较上一交易日减少0.3亿 元。 ...